[Comparative evaluation of methods to determine efficiency potentials in drug utilisation].

Area of Science:

• Health economics
• Pharmaceutical policy
• Health services research

Background:

• Healthcare policy aims to improve drug utilization efficiency.
• Quantifying savings potentials often relies on health insurance claims data.
• This study addresses methodological discussions in determining drug utilization savings.

Purpose of the Study:

• To present and compare four distinct methods for calculating efficiency potentials in the generic drug market.
• To illustrate the impact of different methodologies using Omeprazol as a case study.
• To contribute to the methodological discourse on drug utilization savings.

Main Methods:

• Analysis of claims data from Gmuender ErsatzKasse (GEK) for the year 2005.
• Application of four different methods to assess efficiency potentials in generic drug markets.
• Case study focusing on the drug Omeprazol to demonstrate method variations.

Main Results:

• The choice of method significantly influences the required data and estimations.
• Efficiency potentials for Omeprazol varied widely, from €165,000 to €741,000 (an 80% difference).
• Calculated savings potentials ranged from 2.9% to 13.1% of total Omeprazol expenditures, depending on the method.

Conclusions:

• The magnitude and relevance of theoretical savings potentials are highly dependent on underlying assumptions and chosen methodologies.
• For accurate outcome evaluation, detailed descriptions of the methods employed are essential.
• Drug price considerations at the point of prescription are crucial for optimizing savings calculations across multiple drugs.